Date published: 2026-5-18

1-800-457-3801

SCBT Portrait Logo
Seach Input

β2-chimaerin Inhibitors

β2-Chimaerin inhibitors represent a specialized class of chemical compounds that are designed to interact with and modulate the function of β2-chimaerin, a member of the chimaerin family of Rac GTPase-activating proteins (Rac-GAPs). β2-Chimaerin is involved in the regulation of the Rac signaling pathway, which plays a crucial role in controlling the dynamics of the actin cytoskeleton, cellular migration, proliferation, and various other cellular processes. These inhibitors are characterized by their ability to bind to the regulatory domains of β2-chimaerin, thereby inhibiting its activity. The modulation of β2-chimaerin by these inhibitors can lead to alterations in Rac1 GTPase activity, which affects downstream signaling pathways responsible for cytoskeletal organization and cell motility. Structurally, β2-chimaerin inhibitors often feature moieties that mimic the binding characteristics of natural substrates or ligands of β2-chimaerin, allowing them to compete effectively at the molecular level for the same binding sites.

Research into β2-chimaerin inhibitors is primarily driven by the desire to understand their structural and functional dynamics at a molecular level. This includes elucidating the precise binding mechanisms and conformational changes that occur upon inhibitor binding, as well as identifying the downstream effects on signaling pathways and cellular responses. The development of these inhibitors often involves the synthesis of small molecules or peptidomimetics, which are then subjected to rigorous biochemical and biophysical characterization, including assays for binding affinity, specificity, and inhibition kinetics. Advanced techniques such as X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and molecular dynamics simulations are commonly employed to provide insights into the three-dimensional structure of β2-chimaerin-inhibitor complexes and to rationalize structure-activity relationships (SARs). By gaining a detailed understanding of the molecular interactions between β2-chimaerin and its inhibitors, researchers aim to further elucidate the complex biological roles of Rac-GAP proteins and their regulation, thereby contributing to a broader understanding of cell signaling and its implications for cellular behavior.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

EHop-016

1380432-32-5sc-497382
5 mg
$80.00
(0)

EHop-016 is a selective inhibitor of Rac1, designed to target its binding site for Vav2, a GEF. This inhibition could indirectly modulate the activity of β2-chimaerin.

ZCL278

587841-73-4sc-507369
10 mg
$115.00
(0)

ZCL278 is a Cdc42 inhibitor that may also affect Rac1, thereby potentially impacting β2-chimaerin-mediated Rac regulation.

ML 141

71203-35-5sc-362768
sc-362768A
5 mg
25 mg
$137.00
$512.00
7
(1)

ML141 is a selective inhibitor of Cdc42, a GTPase related to Rac1. While it primarily targets Cdc42, it might have indirect effects on β2-chimaerin activity.

ITX 3

347323-96-0sc-295214
sc-295214A
10 mg
50 mg
$145.00
$615.00
(0)

ITX3 is a specific inhibitor of Trio, a GEF for Rac1, thereby potentially influencing β2-chimaerin-regulated pathways.

PKF118-310

84-82-2sc-364590
sc-364590A
5 mg
25 mg
$180.00
$651.00
(1)

PKF118-310 is known to inhibit Rac1-GEF interaction, potentially influencing β2-chimaerin-related Rac signaling pathways.

SB 203580

152121-47-6sc-3533
sc-3533A
1 mg
5 mg
$90.00
$349.00
284
(5)

SB 203580, while primarily a p38 MAPK inhibitor, may have off-target effects that influence Rac1 activity and thus indirectly affect β2-chimaerin.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$123.00
$400.00
148
(1)

LY 294002 is a PI3K inhibitor that might indirectly affect β2-chimaerin by modulating PI3K-dependent Rac1 activation pathways.